Compare Merck & Co., Inc. (MRK) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares TIPS Bond ETF — how do they compare? Merck & Co., Inc. trades at $130.3 (market cap $323.00B), while iShares TIPS Bond ETF trades at $106.95. The key difference: Merck & Co., Inc. pays a 2.6% dividend while iShares TIPS Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TIP | |
|---|---|---|
Market Cap | $323.00B | — |
Sector | Health | Fixed Income |
52-Week High | $131.84 | $112.20 |
52-Week Low | $77.60 | $106.86 |
Enterprise Value | $369.77B | — |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.45, up 1.46% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, though the P/E ratio of 104.74 reflects high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK is positive, supported by analyst consensus with a $139.90 price target and 67.57% buy ratings. Key opportunities include pipeline expansion via M&A and solid cash flow generation, while risks involve elevated debt levels and competitive pressures in the pharma sector. Earnings beats in recent quarters underscore operational strength, but investors should monitor integration execution from acquisitions.
TIP trades at $107.08 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces headwinds from broader market concerns about inflation and Federal Reserve policy. Recent dividend distributions provide some shareholder return, but key financial ratios remain undisclosed, limiting fundamental visibility.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Investment opportunity hinges on inflation trends and Fed policy clarity, while risks include prolonged bond market volatility and energy price impacts. Wall Street sentiment appears mixed with technical weakness offset by dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
